TY - JOUR
T1 - Visual Pathway Measures are Associated with Neuropsychological Function in Multiple Sclerosis
AU - Nguyen, James
AU - Rothman, Alissa
AU - Fitzgerald, Kathryn
AU - Whetstone, Anna
AU - Syc-Mazurek, Stephanie
AU - Aquino, Jannelle
AU - Balcer, Laura J.
AU - Frohman, Elliot
AU - Frohman, Teresa C.
AU - Crainiceanu, Ciprian
AU - Beier, Meghan
AU - Newsome, Scott D.
AU - Calabresi, Peter A.
AU - Saidha, Shiv
N1 - Publisher Copyright:
© 2018, © 2018 Taylor & Francis Group, LLC.
PY - 2018/7/3
Y1 - 2018/7/3
N2 - Purpose: To determine the relationships between visual function and ganglion cell and inner plexiform layer thickness and neuropsychological measures in multiple sclerosis (MS). Methods: Ninety-five relapsing–remitting MS (RRMS) and 36 progressive MS patients underwent 100%-contrast visual acuity (VA), 2.5%- and 1.25%-contrast letter acuity (LA) testing, Cirrus-HD-optical coherence tomography, and neuropsychological assessments. Mixed-effects regression models were used to assess relationships. Results: Across the cohort, 1.25%-contrast LA was associated with Symbol Digit Modalities Test (SDMT; β = 2.17, p = 0.005) and Brief Visuospatial Memory Test-Revised (BVMT-R) total recall (TR) and delayed recall (DR) scores (β = 0.31, p < 0.001; β = 0.15, p = 0.039, respectively). 2.5%-contrast LA was associated with BVMT-R TR scores (β = 0.27, p = 0.006). In the RRMS cohort, 1.25%-contrast LA was generally more significantly associated with cognitive measures: SDMT (β = 2.97, p = 0.001) and BVMT-R TR (β = 0.32, p < 0.001) and DR (β = 0.22, p = 0.012). Conclusion: This study suggests that visual pathway measures, particularly visual function measures, reflect aspects of cognitive function in MS, further supporting their roles as complementary outcomes in MS neuroprotection trials.
AB - Purpose: To determine the relationships between visual function and ganglion cell and inner plexiform layer thickness and neuropsychological measures in multiple sclerosis (MS). Methods: Ninety-five relapsing–remitting MS (RRMS) and 36 progressive MS patients underwent 100%-contrast visual acuity (VA), 2.5%- and 1.25%-contrast letter acuity (LA) testing, Cirrus-HD-optical coherence tomography, and neuropsychological assessments. Mixed-effects regression models were used to assess relationships. Results: Across the cohort, 1.25%-contrast LA was associated with Symbol Digit Modalities Test (SDMT; β = 2.17, p = 0.005) and Brief Visuospatial Memory Test-Revised (BVMT-R) total recall (TR) and delayed recall (DR) scores (β = 0.31, p < 0.001; β = 0.15, p = 0.039, respectively). 2.5%-contrast LA was associated with BVMT-R TR scores (β = 0.27, p = 0.006). In the RRMS cohort, 1.25%-contrast LA was generally more significantly associated with cognitive measures: SDMT (β = 2.97, p = 0.001) and BVMT-R TR (β = 0.32, p < 0.001) and DR (β = 0.22, p = 0.012). Conclusion: This study suggests that visual pathway measures, particularly visual function measures, reflect aspects of cognitive function in MS, further supporting their roles as complementary outcomes in MS neuroprotection trials.
KW - Visual pathway
KW - multiple sclerosis
KW - neuropsychological assessment
KW - optical coherence tomography
KW - visual function
UR - http://www.scopus.com/inward/record.url?scp=85046115115&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046115115&partnerID=8YFLogxK
U2 - 10.1080/02713683.2018.1459730
DO - 10.1080/02713683.2018.1459730
M3 - Article
C2 - 29634379
AN - SCOPUS:85046115115
SN - 0271-3683
VL - 43
SP - 941
EP - 948
JO - Current Eye Research
JF - Current Eye Research
IS - 7
ER -